Good morning. Thanks for joining. Tim Goodnow. I serve as the CEO for Senseonics. I appreciate everybody participating here on this early hour. Turns out the ADA is pretty restrictive in regards to when we can schedule these things. In theory, we should be done by 8:00 A.M. so we don't run into any compliance issues. I hear things are pretty excited with the ADA these days. I don't want to create any issues. Again, thanks for joining us. As we update you folks on the Senseonics story, it's a pretty exciting time for us. As many of you know, for those that were able to join us a year ago, we had a partnership with the PHC Corporation for the commercial activities. Well, we've transitioned that since we last spoke, and it's a pretty exciting time for us as we've been able to- Thank you. We've been able to leverage that experience and that capability significantly with our strategic investment into the commercial organization. Frankly, we're very excited with the commercial results that we're now getting. Obviously, the control of our destiny is very important because it gives us the ability to pivot and move quickly, make adjustments, expand those areas that make the most sense, and frankly, leverage the internal capability. We've been able to do that because although we did the transition, we've essentially brought the entire Ascensia commercial organization over under Brian's leadership, and that really has made a seamless process that we've been very excited to be able to execute again. We also made the decision as part of that transition in the last year that the primary issue for growth with Eversense in a highly competitive market, but a very attractive market, really had to do with awareness of the product. For us, it made sense that we needed to make a significant increase in awareness, especially at the DTC level, to drive that revenue performance. We've actually seen that wear out. Our partner, although a good, strong partner, was not in the position to be able to do that. As we got to the five-year point of the contract and knowing that we needed to put more into the organization, not less, it just made sense for us to do that transition. People have asked why. Yes, it's a divorce. It's an amicable divorce. They've been a good partner for us. At the same time, this is the time to add fuel based on where we were, really driven by the 365 product, answering a lot of the needs for patients and be able to take it to the next level. We're excited to see some of those results. Obviously, we all know that the CGM market is huge and large. We were well over 25% CAGR. I think we're now around 20% or high teens. Maybe slowing down a little bit as penetration goes in with some of the larger guys. That said, for a company of Senseonics' size and where we are today, we're seeing about 90% of our patients are actually coming from the installed base. The growth opportunity really comes from driving patients through that awareness, through the facilitation of getting them access to the product, to jumping onto it and then making the choice to go with a long-term implantable. We've been successful with that as we've showed. In addition, it's an exciting time. Many are aware. We are on the cusp. There is the expectation. The clinical benefits for CGM have been very clear, right? You continue to provide people with glucose information, they'll be able to act on it. It started out, of course, with the Type 1 indication, the clear recognition. It's gone to the Type 2s that are on MDI. We now have the basal indication. The full expectation is that we will get the huge population of folks that are on the oral agents, the GLP-1s, the diet and exercise. It's just a continuing, expansive opportunity. It makes sense for those people to be monitoring their glucose and doing it with a technology that provides them a facile way while being high quality is an absolute expectation. We're excited to be delivering. As those who've been watching us, we clearly have made some commercial momentum success, and we're going to continue to leverage that and to grow on it. This morning, we'll have an opportunity to hear from a number of folks. Dr. Francine Kaufman, our Chief Medical Officer, will be previewing the real-world experience. We've now been on the market and have thousands of patients that have experienced the Eversense 365. We're getting very attractive performance as measured by the time in range. Continuing that, when you put them on the closed loop, which we'll see with our partnership with the twiist pump, there really is best-in-class performance. That comes from the high-quality product and the compliance that you get with a one-year product, as well as a very accurate sensor, a very good pump, and quite frankly, I think you're seeing some of the value of the loop algorithm that comes from the development of that organic environment. At the same time, we're able to convince and we're able to educate folks on the long-term CGM that our experience with it, that we do offer some benefits that you don't see with some of the other technologies. As good as they are, they've helped a lot of people, certainly with diabetes, but they've really coalesced to the same product at this point, right? They're both 15 days now. They both use glucose oxidase. They generate current. The basic molecular-level technology is slightly different between the two. From a user's perspective, it's a transmitter on the skin, a through transcutaneous sensor that stays resonant for as long as you can keep the wound open or as long as you can keep the adhesive on. It's time to replace it. What it's really come down to for those two technologies is high control of their manufacturing. They're produced in large volume, and as they're able to control that, the one that'll win, quite frankly, is the one that has that best high volume manufacturing. When you see perturbations or you hear complaints about accuracy, or you have recalls, unfortunately, that's going to be as a result of their high volume manufacturing. Again, they're very, very similar technologies. Eversense has been able to answer many of those for some of the patients. Those are the success we've seen, and that's why 90% of our patients, quite frankly. We target existing CGM markets because the market is so large to transition from those. We focus very, very much on the expansion. We're addressing many of the pain points that exist with CGM. We're now at over a $13 billion market, a huge space to participate in. It's an exciting space to be here. Next up, we'll hear from Dr. David Ahn. David is an adult endocrinologist at Hoag. He's Director of the Diabetes Services there. For many of you that watch the space will recognize David as being one of the leaders in the area of patient choice, new technologies around medical devices for people with diabetes, and he's just taken an active role. What a great time in his career to be able to do that, because as it's just exploded over the last decade, there are now so many more options for people that if you're compliant with it and stay with it. Obviously a lot of the questions around how's it going commercially. We'll get an opportunity to hear from Brian. He'll talk about what the transition has been like and why he's been able to be successful here in the last few quarters of really driving some pretty significant growth with the Eversense. Most exciting that's coming, of course, is our Gemini and Freedom products. We'll certainly give you a little bit of an update, see some encouraging data on the early concepts for Freedom and why we're seeing success with the Bluetooth incorporation, of course, the questions we always get, what's the timing? How's it looking? Then we'll ask Rick to wrap up and do some financial discussion. As many of you know, we recently did a significant funding round that's given us the opportunity to go ahead and make this investment in the technology as well as the commercial execution. As we look at the opportunity, obviously, as I said, it's huge. It continues to grow because of that need in the diabetes space for glucose monitoring, and we will continue to see success associated with it. Eversense, of course, is completely different. We've designed the technology because we knew there are a lot, and for many of you get an opportunity to go to- You don't see it here in the U.S. because of the FDA approval, but if you go to the corollary meetings in Europe, you'll see a lot of the Near East competitors in the transcutaneous CGM. There are multiple systems that are out, 10, 14. There's even a new one for 21 days that are transcutaneous CGMs that are really trying to capture the low-cost market. They don't have the accuracy requirement to come to the U.S., so they haven't been submitted for the indication. Of course, the barrier, which is a reality today for the iCGM designation, is even that higher standard. Unlike a few years ago when we saw a lot of offshore competition come in in the strip and meter business, it's going to be a higher hurdle for people to come into the U.S. to bring some of those knock-off markets. Never mind the market dynamics or IP dynamics that go on that are associated with it. What you really do see in that space, of course, is they're really capped at about 15 days. The reality is that that wound that you create to put the sensor is going to close up, it's going to heal, and the body's going to want to go back to its native state. Then you have the adhesive issues and the dynamics. As you get more and more aggressive to stay on longer and longer, you're going to get more and more skin reactions. Where they've really focused this is in two domains. You're well aware of this, is really about transmitter size. How small that we can make it. Everything you're trying to do is make it less intrusive for folks. You've seen even now with the announcement of the G8, they're really going to be approaching Libre size in regards to the transmitter. Obviously, that's not a space that makes sense for us as an implantable to focus in. We do have a transcutaneous component for it today called the transmitter, but we're working very hard to eliminate it, and that's ultimately the Freedom product. We're fully incorporating all the components. We'll be the first folks that have nothing on the skin, and that's really our point of differentiation. We'll be able to leapfrog the technology that's associated with it. We'll spend some time talking about it, but obviously, we're pretty excited. In regards to the commercial strategy, Brian will go into much greater detail. As I said, for us, it really is about awareness at our size. Once people understand that there is an opportunity for a year-long sensor, they're willing to give it a try. The one hurdle that we go through that we work significantly on, and many of you are aware of it, is through our ION network, and that's in regards to access. We have good coverage. That's not been an issue for us, but you want to make sure that it's easy for people to get the sensor and get the product. Our expansion of the ION nurse network, which is now at around 80 nurses, has really given us and really taken that burden off from us as a company and allowed us to give it to the patients as an easy access. We're pretty excited about the progress that we've made there, and we're working on penetration. We're going to more clinics, and we're going deeper in the clinics. Then finally, of course, what's very, very important, we're starting to see some of the fruits of that labor, is the retention. People need to feel that this is the right product choice for them, and they're willing to come back. We do see that. The product, especially after they've been on it a couple of times, if you've been on two sensors now, that's two years of your life. You're really committed to it. We're seeing a lot of the folks come back, and I think David can certainly speak to what his experience is with his patients in regards to how many will be able to use the product over and over again. Exciting times. Now that we are fully integrated, it is an exciting time to be with the organization. We had the full team together. You can feel the energy. Some success that we've seen with commercial has really allowed us to be a little bit bolder with our step and feel very encouraged with what we're going forward with. It's allowed us to make changes and change some of the acceleration. Importantly, obviously, the change also significantly changes our financial profile. Not only do we, of course, get to recognize all the revenue now, but that, of course, all falls through. As you've seen, we've been able to publish some pretty exciting margin profile for a company of our size, and that's driven by the once-a-year disposable. As opposed to a two-week sensor, instead of producing 25 sensors to keep that patient for a year, we only have to produce one. We get to leverage that denominator pretty significantly. A little data to support that. New patient growth, this is Q1 data. We'll obviously have Q2, obviously, there's significant growth. As we've seen in the first quarter, we saw over 100% growth in the DTC patients and a 40% growth in the HCPs. The sales team is doing a great job. The DTC is really driving that awareness. Not only do we have folks that come in through the web, and we facilitate that process, but they also come into the sales reps as well. They'll go to their doctor, or they'll do a Google search on Eversense, and they'll come in through their doctor even though they were stimulated by our DTC commercial advertising. It's really helped in both domains. As you know, CGM is a very high touch. It's like the pump space. The patients do want to spend time. They do want to get to know their sales folks. A lot of our sales reps carry the cell phone numbers of their patients, will take really the first questions. The inserter growth has been significant as well, especially with that Eon Care. That's up over 900% year-on-year. It's really been a major focus for us. It's one of the key strategic changes that we've made that's really facilitated the process. We get asked a lot about the prescribers. They continue to grow very nicely. They're up 80% year-on-year in the first quarter as well. That's resulted in the growth that you've seen in the revenue, and we continue to hold guidance at $60 million-$64 million for the year. As we look at Eversense, clearly we are a difference maker. We're going to continue to leverage that with the new technologies that come out. There's a lot of folks that are excited about the future with what we can do with the Gemini and Freedom products, and we really look to, at that point, really be a difference maker in the space by driving folks to the highly innovative concept. We'll do that. We'll certainly, of course, take larger market share as a result of that, both with patients that are switching, which is where we focus our attention now, but new patients that are coming to the market as well. With that, we've started in an environment, of course, with the short-term CGM. They've helped a lot of folks. There are millions and millions of patients on it. We're going to continue to support those. We've entered the first long-term CGM, but we want to take it to the next step. We're going to make it invisible for folks. We have an exciting platform. We'll be able to continue to do the exact same insertion that we do today. It'll last for a full year, but it's completely invisible for folks. We're not in the race to reduce size of transmitters. We're going to leapfrog that, we're going to jump right over that. With that, I want to thank everybody again for your time today. What I'd like to do is introduce Dr. Kaufman, they could show you just exactly how the product has been performing since we put it on market about 16, 17 months ago. Thank you, Tim. Good morning, everyone. For me, from the West Coast, this is really early morning. My goal is to dazzle you with some numbers that we have now, and I will be presenting later today at the conference our latest numbers. We'll go from this 5,000 sensor area, which I presented at ATTD, to 12,000, as well as an increased number of patients on the twiist integration and their real-world data. Just really excited to dazzle you with what these are. We're able to anonymize our sensor glucose data from our data management system and look at the glucometrics. We do ask the patients to identify themselves as far as whether they have Type 1 or Type 2 diabetes and their age, as well as a few other metrics about themselves. We've been able to also write a manuscript. We've submitted it now to [DT&T], and we're waiting to hear. I'm going to show you the first 5,000, and later today, I will be again presenting the next 12,000. The mean age of our cohort is 55. You can see the distribution by gender, we are a predominantly Type 2 cohort. All of these patients are in open loop, either with MDI, including with Afrezza, or on open loop pump therapy. Then when we look at the number of data points we can get per sensor, the mean is almost 28,000 data points from a sensor. Here's what the data looks like. What we wanted to do was compare the first six months to the second six months of Eversense wear, and then aggregate that data and look at the entire cohort. When we look at the wear time, it is truly impressive. The patients are using their transmitter on- body 93% of the time, which means they're generating glucose data that allows them to manage their diabetes, as well as generating glucose data that they can look at retrospectively, either on their own or with their healthcare provider. Then obviously, mean sensor glucose value is very important, and we're talking about 160. Also the GMI, the glucose management indicator, which reflects what the A1C would be, is 7.14. I think you can see when we compare the first six months to the second six months, there's no decrement in these numbers over time. If we look at how are these numbers actually distributed now, we've kind of all agreed on what these buckets of glucose values are. The hypoglycemia range, the time in either tight range or the time in range between 70 and 180, and then the hypoglycemic values. Then we can look at from the consensus data, what we're really aiming for our patients, which is the percent of patients with less than 70 mg/dL, less than 4% of the time, and less than 54 mg/dL, less than 1% of the time. When we look at it again, there's no difference between the first six months and the second six months, so we can look at the data aggregated and see that we actually have very little hypoglycemia. What is this attributed to? It's obviously attributed to the fact that these patients are using their transmitter, are using the Eversense, and as well, they don't have these periods in which they're switching out one CGM for another and maybe I'll take today off, or maybe I just won't use this data at all and I'll wait to put another CGM on. I think that enables them as well as our settable predictive and threshold alerts, really enables them in open loop to acutely manage their diabetes. We can look at time and range, and at 66% of the time, again, in open loop, where really the goal is to be 70% of the time or greater, and that was really designed for closed loop kind of therapy. Now, interestingly, we can look at by age cohorts or age buckets from young adults all the way through the Medicare age range and see that actually all the glucometrics improve with age, which is what we've seen across all the Type 1 and Type 2 patients who really, as they get older, maybe it's a survival issue or they're more acutely able to manage their own diabetes. When we look at the Medicare age range now, we're getting to the kind of values that are the target for closed loop. A mean glucose value that's really acceptable of 154 and a mean GMI that's below 7%, reflecting likely what their A1Cs will be. Even in the young adults who have the least favorable outcomes across the board in any study we look at, our values are really pretty good with a mean GMI of 7.32. We can look at all these glucometrics. Again, we see that with increasing age, improved outcomes, so that by the time we get to the Medicare age range, we're above 70% of the time in the values between 70 and 180, very little hypoglycemia, and now greater than 85% of the patients meeting the hypoglycemic targets. Really the kind of outcomes that we're hoping for our patient population. That's the real-world data in open loop. Dr. Ahn is going to talk about the twiist integration and some of our real-world data now with that integration. I thank you. The goal was not to fall off the podium. Yeah. All right. Great. I'll tell you a little bit about myself. I'm an endocrinologist for adults. I'm the Chief of Diabetes Services for a regional hospital in Orange County, California. This is a beautiful view from Newport Beach. I've been supporting Eversense or using Eversense in my patients essentially since it launched. I've had hundreds of sensors in my patients. As Fran mentioned, I really am a big fan of choice and having options for patients because every person with diabetes has a different experience, different preferences, different needs. I've done over 350 of these procedures. I do insertions for patients in my panel. I also end up being a referral center for people nearby. I'll just be the proceduralist for those patients and then send them back to their endos. It has not been a huge issue fitting the procedure into my practice, but it's great that Eversense also has that network for the clinicians that don't want to do the procedures. Essentially zero adverse events related to the procedures over my, I guess, eight years now, and my patients really love Eversense, and you'll see why. When they announced that their partnership was going to be with twiist, or their initial partnership was going to be with twiist, I was really excited because outside of maybe the big two or three, I think the twiist has a lot of unique advantages that I think would help support kind of the strength of the Eversense. To kind of summarize, I'll go into a little bit of detail on some of these line items, but the twiist has a lot of customizability, and I think a lot of kind of like the Eversense, I think it draws in early adopters. It's also usable at scale for kind of your average person with diabetes as well. It kind of has the optionality to be very precise, to have a lot of finesse and kind of levers to adjust. If you set it up in kind of a standard way, you can get a really good experience, even if you're not that type of person who likes to tinker. Some of those things that are really unique about the twiist is that it has the lowest target setting of 87 mg/dL. You can have various targets throughout the day, and you can also have it go really high. It can be for the person who wants to run really low. It can also be for the elderly, grandma who is worried about running low and would prefer to keep her glucose numbers higher. It also has the ability to do a couple modulations to the algorithm that none of the other commercial systems can. There's something called like a pre-meal override, where you can set a temporary target that's lower going into a meal. It also has the ability to pick different speed insulin action profiles in its calculations with a very simple option of a lollipop, a taco, and a pizza, and the user can just kind of say, "Oh, my meal is going to be a really quickly absorbed carbohydrate like a lollipop," or it might have kind of a double wave pattern or an extended pattern like a pizza. One of the unique features of the twiist system is their iiSure technology, which allows it to detect occlusions much faster than other systems. You can see the minutes listed here, but I think they're advertising about at least 5x faster than other systems, and 5x faster than the next competitor and up to 10x faster than some of the other competitors on the market. The twiist does hold 300 units as well, but is still relatively sleek. It does kind of have a little bit of the best of both worlds there. Of course, the Eversense 365, you've heard a lot of the advantages of it. I can't iterate enough that I think a lot of the patients that are drawn to the Eversense are also drawn to twiist, so I was really excited to kind of see that partnership happen. This is some real-world data that Fran presented. I would imagine Fran. It was Fran, but I wasn't there specifically. They shared some real-world data from their first initial wave of patients going on automated insulin delivery. This is the data that I was really looking forward to hearing because whenever there's new technologies, as much as I like it on paper or as much as I like the sensor in my patients, I always want to see how patients actually perform with it. I was kind of nervous for how it would actually work in the real world. As you can see here from their full commercial launch in February 19th, they did their data analysis on March 2nd, and this does include patients kind of in their early- They had some patients start slightly earlier, as you'll see in some of my test cases. They looked at 122 sensors for patients that had at least seven days since integrating with twiist. The average age of patients was 45 years old, and 64% of them had Type 1 diabetes. Once again, the median transmitter wear time was very high, 99%, which is very impressive because patients can take it off and put it back whenever they want. The fact that they're wearing it 99% shows the value that they're getting from the system. The average sensor glucose was 144 mg/dL. The GMI was 6.76%, which is fantastic. Under 7%, of course, is our goal. In the box on the right, you can see that the time and range was 76.6%, which is a very impressive number. The time in tight range was also very impressive at 53.94%, with very little hypoglycemia at 0.5% in the less than 54 mg/dL range and less than 3% in the less than 70 mg/dL range. I'm going to go through three cases, and these are all patients in my panel, so I know them and their stories pretty well, and I think they represent kind of different situations that all really benefited from both the Eversense and twiist integration. The first patient, she's a 31-year-old female, diagnosed at the age of 12. She had been on open loop pump therapy from diagnosis. I had met her kind of earlier on when she was on Eversense. Initially, she was on MDI, and then she went on a Medtronic pump paired with the Eversense, and then she eventually went on twiist. Her issue with the other sensors was that she had very sensitive skin, and she had concerns about the accuracy of these systems, and she felt like it was not very accurate for her. Over time, prior to going on Eversense back in 2019, her A1C had been rising. She had been having very variable glucose levels with highs and lows, which makes it really challenging for us as clinicians. Until she started the Eversense in 2019, which she tolerated without skin or accuracy issues. Naturally, over the years, she's been very excited to go on an AID system, but it needed to be one that integrated with Eversense because she only trusted that as her sensor. She was part of the limited launch starting in December 2025. This is some of her data back before 2019, this is when she was on the Medtronic system. She's using a Medtronic without CGM, just the pump, but no CGM. As you can see, orange represents high numbers and red represents low numbers. The bulk of her numbers are either too high or too low, which for us as clinicians is very challenging because then you can't just ratchet up insulin therapy or back off because you kind of have to finesse it a little bit more, which is why automation is so important. She then added Eversense to her open loop journey. In this picture, she's now using Eversense with a Medtronic system. As you can see from this day for her, she's having much less hypoglycemia, and her time in range in this statistic is 67%. She was getting pretty decent control. Her time spent low had significantly improved. This is her first two weeks on Eversense 365 after integrating the twiist. Sorry, this is more recent data. She started Eversense 365 with twiist in December, and this is data from April. You can see that her time in range is now 76%, and her standard deviation is 50, and her GMI is 6.8%. For reference, that's an improvement from her time in range of 68%-76%, which is a very significant improvement. For someone like her who had been waiting so long for an AID system and the benefits of automation, this has been really liberating for her, and just kind of seeing her come back and really perk up, because as we all know, there's only so far you can get with open-loop therapy. This is just an average day looking at her experience with twiist and Eversense 365. As you can see, very little hypoglycemia, and she is having much less hyperglycemia as well. On this specific day in question, her time in range is 81%. Of course, the overnight periods are fantastic, as is the case with automation. The second case report is a 29-year-old male. He is a police officer who is now part of the SWAT team, but SWAT in Irvine, California, is probably less exciting than other parts of the country. He had been on Eversense and MDI since 2020, and he had chosen Eversense because of adhesive issues. He found that with his jacket and his equipment, sometimes it would fall off, and he would then be off a sensor until he can get back to his locker. Also, he preferred the vibratory alerts. He didn't want to hear little chirps and beeps while he's doing his work. He had been on Eversense since 2020 and was very excited to get the benefits of automation and start the twiist. He started on January 2nd, 2026. Just for reference, his background A1C was 7.5 in November of 2025, and this is his last two weeks of data prior to going on automation. As you can see, he runs a pretty tight ship. His time in range is pretty good at, I think that's 61% or 81%, and his average glucose is 143. The thing that stands out to me as a clinician is obviously the significance of his low blood sugar numbers. Obviously, that's something we don't want, and it kind of artificially makes his GMI, A1C, and average glucose look good. This is the improvement that he had over time. These are literally the first two weeks that he was on the twiist system. His time in range improved to 80%. Sorry, I think that initial number was 61%. A significant improvement in time in range, and his time spent low had decreased significantly and is now at the ADA recommended targets of 4% and 1% for time spent low and very low. The other thing I think that's very meaningful is his average glucose significantly improved from 143 down to 132, and I think this is kind of a nice side-by-side comparison looking at those two data sets. It's the same data sets I just showed you, but kind of side by side. The funny thing is, if you look on the right side of the screen, that first night was actually, it's including the day that he got trained. My mouse isn't showing up, but y ou can see that the top left box on the right graph, that night period where he ran high was actually before he started the twiist system. If you take out that chunk, his overnight period would be even better. Overall, you're reducing lows, improving highs, and overall, he's been really thrilled with the system because he doesn't have to worry about it as much on his shifts when he's working. My third and final case report is a 41-year-old male. He had used Eversense in the past, I had met him, I think, around 2020 initially. He's kind of an early adopter type person. He always wants to try out the latest technologies. He found that some of the other transcutaneous sensors were lacking in accuracy. He had ended up going back to Dexcom because it was the only system that integrated with the Omnipod, and he wanted to wear an Omnipod and have automation. He started to get intrigued- He felt like the algorithm was not aggressive enough for him, and he wanted something that gave him the option to have a lower target. He ended up starting the twiist and the Libre initially, because that was what was first more easily available to him in March. This is his data when he was on the Omnipod and Dexcom. His time in range was pretty good. I think that's, yeah, 88%. Obviously, his performance was doing pretty well, but I think it's also, you'll see his average improved quite significantly over the next couple slides. His average glucose was 141, but overall doing well, but to his preference, he wanted to run lower, but he felt like the system was not allowing him to have a lower average glucose. Initially, he went on the twiist plus the FreeStyle Libre 3 Plus because that was the fastest thing he could get on at the time. His time in range went down ever so slightly to 85%, but his average did improve from 141 to 136. Eventually he went on twiist plus Eversense 365, and then you can see that his time in range improved to 93%, and his average sensor glucose dropped to 112. That's from a baseline of 141 down to 112, which is hard to do, as you might imagine, in the real world. As you can see, he was able to achieve those goals that he was trying to do to improve his average and improve his time in tight range. Yeah, I think this slide kind of speaks for itself. To conclude, my patients first were getting a lot of benefits of the Eversense 365 CGM experience in open loop, but really those improvements get exponentially increased when they integrate that with twiist and an automated insulin delivery system. My patients really love Eversense 365. You can see that many of them returned to Eversense 365. There are a few other patients I can think of that also had switched away from Eversense, but came back now that it was an option with automated insulin delivery. I think it's really important, I kind of preach this in everything, but what I love about Eversense is that it's a unique system with unique benefits and profiles. I think what Tim shared earlier, where a lot of the other sensors now have similar benefits, similar limitations, whereas the Eversense has very unique benefits and disadvantages, and a lot of those benefits are in the exact areas where some of the transcutaneous sensors struggle. Pressure lows are a common frustration, day one inaccuracies are a common frustration, and of course, the Eversense has one day one every year. I think choice is really important, and I enjoy doing the procedure, and I hope more patients have the opportunity to get the benefits of Eversense and twiist. Thank you, Dr. Ahn. As a commercial guy, I really like watching that, right? What Fran presented, what David presented. When we went through our clinical trial process, I was very concerned that if it wasn't going to make it one year, what were we going to name it, right? Eversense 340 wasn't going to sound near as good. We had the real-world data come, and we weren't quite sure how that was going to look when we presented ATTD to see it perform just as well on day 365 as it does on day 180 or 90 or 20, makes my job much easier. The fact it survives as well all the way through is quite a testament to the work Hari's doing, Mukul will talk about it a little bit, but as a commercial guy, we have a product that we can really stand behind. David, what I really liked what you said is offering choice, right? If we can offer choice to our patients, everybody wins, and I think that's something we certainly strive for. You guys have seen this slide before. We've really tried to work on scaling. We've really tried to make our product more available to patients, easier to prescribe. Does certainly start with driving volume. The more volume, the more opportunities we have to put people in place to insert it. The more volume gives a better seat at the table with payers, with physicians. As Tim said, our DTC marketing, we did so much of it in the second half of last year. We learned a lot from that. We learned what levers work, what levers don't. We'll talk about that in the next slide. It really was optimizing our awareness that really has driven some of the success in the early part of the year, making it easier to get our product. Again, we'll talk about our Eon Care network here in a second. Tim said that expanded coverage has really made a difference. We're getting more from our existing physicians. Our field really focuses on that, not only driving our DTC opportunities into new clinics, but also those that are using it, doing more. I was out with our largest clinic for dinner last night. Their plans to expand continue to amaze me. Why? Because the system works for them, right? There's an economic advantage to inserting it, but when they do insert it works very well for their patients. It's a win-win on both sides. Obviously retention. That number continues to get bigger and bigger. It's easier to keep a patient than it is to go get a patient, and we're seeing really good results in our early stages of renewing our 365 patients. It's really making sure that one-year patient is going to two. Tim will always say, once they get to three, four, or five, they tended to stay very consistent with the product, very pod committed. We have a lot of programs in place right now to make sure we walk with that patient all the way through that year journey, and when the time comes up, we have them scheduled, we have them ready for an insertion, and there's no lapse there in care. We won't go through this any deeper than we're seeing 60% of our business come in from our direct-to-consumer advertising channel, 40% from our efforts in the field. Trust me, the field does support the DTC piece as well, and it does open up new doors, but there's a lot behind what we have going on. At the end of the day, John and the marketing team really is looking to drive workable leads that our inside team of 55 inside sales reps can go through and drive a higher percentage to close. We could get many more leads in if we throw a wider net, then you sit there and get a bunch of leads that don't qualify, not on insulin, don't have proper insurance coverage, outside our coverage range of insertion. We're very targeted in our DTC spend, and we spend about $1 million a month. We'll up that a little bit here in the second half of the year, but it's driving in right now some very high-quality leads, and we're seeing our metrics move in a very positive direction. Our territory coverage in the U.S., roughly 45 territories supported by some clinical individuals, some management team. Many of these folks have been in the diabetes business for a while. You guys know this across the industry. We're all kind of incestuous and have worked around. Some of my friends have joined us over from a few of my prior lives, but we're very happy with our team, and our entire team came over. We saw literally no turnover in our transition from Ascensia to Senseonics, so we're very proud of that. As we look into next year, we'll see where we can start to add a little bit here. Getting the raise has helped a little bit. Tim has said we'd like to expand some. We're going to do it smart. The more we can add inserters, the more we can add reps, the more we can increase where we are advertising, because we do geo-fence our DTC advertising. We just don't advertise in 50 states in all counties. If we can't insert, if we can't support, there's no reason to do that. The more that I can expand, the more I can do on the DTC side and allow us to get to more patients and physicians. Eon Care. This is something that we decided to do roughly about a year and a half ago. We had partnered with a nurse practitioner group. Kelly and Jeff in the back there are instrumental in building this out, but we made a decision we wanted to control our own destiny here. We finished the year with about 35 inserters. These are 1099 nurses typically for us that are doing the insertions, trained by us, become really, really good at it. They've really become partners with us, and they're also really good at educating the patient pre and post. It takes some burden off of my sales team, which they don't need to be spending that time doing. They need to be selling when they can. We have a goal to get to 100 by the end of the year. We're roughly at about 80 now, so we've done a great job in the first half of the year, adding strategically where our commercial team feels it's important and also where we can drive additional volume. Again, sometimes there's a chicken or egg here. Sometimes we'll put somebody in a market that we want to grow, and then we'll start to really hit that with our reps as well as our direct to consumer advertising. This has been a tremendous success for us. There is good economics to this as well. This pays for itself. Ultimately, as we build it out, it'll be a very important part of our both commercial and growth strategy. 90% of our folks are coming from another sensor, which is great. Right? Certainly they are more familiar. They're easier to onboard. 10% are CGM naive. Again, we get a lot of very positive feedback for the performance of our system, and that's certainly something that we're always proud of, that the system works tremendously well. Once somebody does try it, and when someone has access to it tends to be very sticky. As Fran and David both said, it's used quite often, right? The persistency is there. Super happy about our relationship with twiist. One of the things for me as a commercial guy with twiist is they have 100 territories. I've been able to amplify my small team's voice through their partnership and vice versa. We're bringing new patients to twiist, and they're bringing new patients to our Eversense product. We've actually exceeded, by quite a bit, how many have combined systems or are using the combined system. My eight years at Tandem, there was different uptakes when we did different versions of CGMs with our pump, but this went much faster than I expected. I know you all want to ask, are we doing additional ones? The answer is yes. Tim and Mukul and I will be meeting with our normal friends as we're here at the show. Right now, we're really focused on this, and then hopefully, we'll be able to do some additional integrations here over the coming year or so. In Europe, we have transitioned successfully three out of four of the countries this past week. They've come from Ascensia to Senseonics. They're now fully over as Senseonics employees. Our general counsel in the back there, Ken, can you say Italy will be Monday, I hope? We are close to the last one. We've had a transition service agreement with Ascensia all along. They've been great partners. As you know, I came from that team, so it really hasn't hindered us, but we're looking forward to getting everybody over. We have now replaced the BGM sales efforts with our own sales reps, and about 95% of those folks have either been identified or hired now by us. We're going to have very focused and targeted commercial and sales efforts in those four countries. 365 has launched in Sweden and Spain already. Germany will go here next week, and we just need to move some of the tenders over in Italy, and we'll be launching in Italy here, most likely in July timing, but there is certainly some pent-up demand. We will have 365 in all markets, which Rick likes because that helps the margins. E3 will transition out, and then we start to move towards Gemini. That is my quick slides, and Mukul will talk about Gemini and Freedom and how easy it is to get those to me. Right there. Right there. [crosstalk]. Thanks, Brian. Always difficult to come behind a commercial guy. When we set out on this journey a long time ago, when we started with the 90-day and then 180, but we always had this one vision in front of us, get to one sensor that will last the full year, get rid of those daily calibrations, that was a burden, and then no transmitter, no on-body component for the device. We have achieved the first two. We do not have any changes for the entire year. No daily calibration. With the weekly calibration, we have on Eversense 365. Now we are looking at how do we remove those transmitters completely. To look at that, the two things that the transmitter does today is to power the sensor for every reading because the sensor does not have a power source. It powers the sensor. The second thing it needs to do is get the data out from the sensor. It takes the RF through RF, gets the data out, sends it over to the phone by Bluetooth. Those are the two functionalities we need to build into that sensor. We are able to do something that other CGMs cannot do. No on-body component for a CGM that works the entire year. We set out on this journey, and we are right there knocking at the door now with Gemini, which is the first step of adding a battery. In this version of the product, we have added a battery to the sensor. We went to the battery company that is very well known for implantable devices, Integer, or for people who have been doing this for a while, Wilson Greatbatch. They had a battery. They made it small enough for us. Now we can basically get the sensor to collect data every five minutes. To get it out, we still need the RF energy. We still need to either get it out with a phone. You can scan it with your Google Pay, Apple Pay, the RF that you have on the smartphones, or you can wear a transmitter, which will continue working at a full-service CGM. Now you have a combination, the flexibility in one sensor to either use it as a flash, FGM mode, or as a full-service CGM mode. Most important here is we kept the same sensor that we have heard from Dr. Ahn, Dr. Kaufman, and from Brian. We have tremendous success with the 365-day sensor. The Eversense 365 makes FDA very comfortable. They know that the sensor works. All we are doing now is taking the new functionality that we have that we need to prove out, which is how do you get the data out with an intermittent scan? That's Gemini. Then the next stage beyond Gemini is to get communication inside the sensor, which is the same Bluetooth communication. There are many other implantable devices that use Bluetooth, but none of them use it in the size we are talking about. That's the challenge in front of us. That's the one we are solving for. I'll talk about the timelines and where we are in those two programs. Here, this is the Freedom product where you have taken out the RF antenna, created room to put the Bluetooth chip and the Bluetooth antenna. We are basically keeping the same sensor, keeping the same form factor as Gemini here, and now going on to have a sensor that is fully implanted with no on-body. Where we are with the Gemini, we are currently in a pivotal study in the U.S., plan to finish it up by the end of the year. The study is a three-month study. The patients are enrolled for three months. They come in, they are wearing Eversense 365 on one arm and the Gemini sensor on the other arm. They go through the clinical session, and at home, they are scanning that device many times. That is what FDA wants to see, is the reliability of that scan feature, and that is all we are trying to prove to them. We finish it up end of the year, submit it to FDA. Since we are keeping the same sensor, we keep the same performance, iCGM designation, do a 510(k), and expect to be on market by Q2 2027. Right behind, we are already doing a lot of work that I'll go through in the next few slides on Freedom. That's pretty much running about one year behind it and expect to be on the market in the second quarter of 2028. Talk about Freedom. Same sensing. Talking about communication, we were able to find the right-sized Bluetooth chip off-the-shelf and a Bluetooth antenna that works for us. We are basically putting all that together. We have done a few iterations in technology, done a lot of testing, both on the bench and a couple of animal studies now. I'll show some data from the second animal study that we are still kind of concluding, but I stole away from the engineers. From the battery perspective, while we were working on Gemini, Integer was able to put in a second-generation chemistry in the same form factor. That was the challenge we put in front of them, is to not grow the size of the battery, but get me more juice in the battery so I can power the Bluetooth. They were able to do that. We have about one month buffer where we stand on today's Bluetooth communication that we are running, obviously, we are trying to refine that with external partners, better protocol, so that we can get it to be even less power hungry. Today, we already have a one-month buffer. For our 12-layer, whatever our power budget is, the battery has proven to be more capacity than that. The battery is finishing up. They already have batteries for us that are in a first-in-human coming up, and then they'll finish the verification testing end of the year, be production ready by Q1 2027. We just concluded an animal study. Again, this is some iterations of bench and then going into. Oh, sorry. Animal study. Three animals, pigs, and we had two different antenna variants that we were trying to figure out. One was hand-wound helical antenna, and other one was just off-the-shelf that we call the Johanson, based on the name of the vendor. The way we were doing it was looking at a couple of locations on the pig. These were early prototypes, you can see that RSSI is the lower number. Lower absolute number is better. That gives you the strength of that Bluetooth communication. This was a somewhat free-form study. This data shows you an aggregation of 50 days, about 18,000 points, I believe. It's basically let those animals move around in enclosures, and we tried three different enclosures, starting with an 8-feet enclosure, then going to 15, and then going all the way to 25. This is basically just looking at what works and what doesn't work. Very directional study. As much as we would have wanted many more greens, this is very exciting. What it tells us is Johanson antenna, which is basically off-the-shelf, I don't have to have somebody wound an antenna. That works for us. We have configuration where we are seeing 100% success rate when you're within 8 ft. Think of the typical use case. Most of the other implantable devices using Bluetooth are always labeling it up to 6 ft, arm's length. This, we were able to get up to 8 ft, 100% communication, and then varying, when they're allowed to walk up to 25 ft in that enclosure, we are seeing, in some cases, up to 83% connection. This is a really exciting start. We are still looking at the data. They are still trying to understand when the failures happen. We had cameras in those enclosures, so people are trying to figure out when do we really lose communication? What does it correlate to? Overall, we are very excited where we are today. What this does is get us ready for building a sensor for first-in-human, which is the next step. We plan on starting a first-in-human study somewhere in early Q3. That should give us the confidence and the data to support a pivotal study, and go to FDA looking for an IDE at the end of the year, early next year. From there, get into a pivotal Freedom study in 2027, finish it up by end of 2027, go through 510(k) Q1 2028, and get in front of public by second quarter. That's where we are, and we can talk more about it later. Thank you. Rick? [audio distortion] Thanks, Mukul. Good morning, everyone. I'm Rick Sullivan, the Chief Financial Officer at Senseonics. All right. Let's start with the financing last month. We raised over $100 million of growth capital through both an equity offering and an amendment to our debt facility. This should provide us enough capital, we believe, to fund us through the launch of the Freedom product. The equity offering was just about $90 million of net proceeds. It was really led by five institutional investors that had really strong conviction in the Eversense story. We appreciate their support. Hercules Capital's been our lender for a number of years now and provided an amendment that gave us access to $20 million immediately, and then have another $85 million that will be available over the next 18 months, with the first piece of that being available later this year. From a pro forma perspective, certainly improves our balance sheet with over $160 million. The $60 million we finished the quarter with, plus the more than $100 million we raised. Then from a fully diluted position, we had about 52 million increases to 70 million shares outstanding. All right. For the past couple of quarters, I've tried to describe in lots of words on our earnings calls, the revenue streams and different channels of the business. I thought a visual might be helpful. Brian spoke about our sales channels, the DTC channel, with the advertisements, the about $13 million we plan to spend this year, social media campaigns that are supported by that inside sales team. The HCP channel, which is the territories, the sales reps calling on physicians' offices across the country. Then our reorders. As our patient base grows, the reorders will become a bigger piece of our business each and every year. Next are the reimbursement channels. Our product's reimbursed through two primary channels. One's DME. It's durable medical equipment through distributors that have contracts with insurance payers. It's about 40% of our volume. This is historically how CGM has been reimbursed. Through the distributor channel, we have distributor margins, there's prompt pays, there's rebates, and our patient assistance program is more heavily utilized through that channel. On the other hand, is bundled pay, which is the bundling of both the product and the procedure. Because we don't have those gross to net adjustments from the DME channel, and we have Medicare included in the bundled pay, which reimburse at a premium, we do see higher ASPs and more of our business is now flowing into that bundled pay channel. Historically, it'd been about 50/50. We did spend some time trying to optimize that channel and are now at 60/40 and expect to remain there for the remainder of 2026, but do foresee improvements in future years. That leads us to revenue. Distributor. First is the distributors. Those are the ones that service the DME channel. They typically hold 30 days of inventory. We recognize revenue upon our shipment to those DME distributors. Eon Care actually does support those DME distributors. A patient would get the product from the DME channel. The Eon Care would do the procedure through a referral, and we would be able to bill those CPT codes just for the procedure. There is some procedure-only revenue that comes out of our Eon Care network. Eon Care also supports both Medicare and the commercial payers that use the bundled pay. In that case, Eon recognizes the revenue upon insertion for both the product and the procedure. We have our consignment program. The consignment program is when physicians elect to enter into the program. There's a couple hundred today, where they'll have product on their shelf. When a patient's ready, they'll perform the procedure, they'll bill for it, they'll collect payment, and they'll keep the procedure fee for themselves, and they'll remit the remaining product fee back to Senseonics. We had a very strong first quarter. Q1 for our industry typically has seasonality, we see declines there with deductibles resetting, higher patient assistance utilization. We also had the commercial integration that we needed to do as we brought on the Ascensia organization, we still overperformed. That overperformance was certainly a result of the revenue share being eliminated with the Ascensia partnership, but also some of that shift in sales mix to that bundled pay. Really just the continued execution. There was minimal disruption with the commercial integration. Margins were really good. We're very excited about that. Some of it's with that sales mix. A lot of it was because we're now manufacturing a 365-day product globally, for the launch of 365 in Europe. Also, we did see this one-time benefit. It wasn't quite 58%, back that out 54%, still stronger than we thought. I think that led us to our guidance for 2026. We increased our revenue guidance to $60 million-$64 million, representing more than 80% growth year-over-year in revenue. We raised our gross margin guidance 55%-58%. We're able to keep our operating expense and cash utilization the same. I think this really sets us up for the future. We do expect to continue to see significant growth with our current product, but also the Gemini and the Freedom products. That Freedom product, having a single sensor for a year with no on-body component, eliminating some of the components, and at scale, we do see margins growing beyond 70% with that product. That'll allow us to be both EBITDA and cash flow profitable in the next several years. I think you've heard from everybody today. Tim outlining the corporate strategy, from Fran talking about the very strong data that our product has, Dr. Ahn talking through the patient experience, Brian's commercial strategy, and our product pipeline. We're really excited about where we're headed. This year is really just the beginning. With that, I think I would like to open it up for Q&A. Thanks for hosting this event. Very informative. Appreciate it. Josh Jennings from TD Cowen. I think first, Brian, you mentioned just seeing the data at ATTD and again here today that, as a commercial guy, that's exactly what you're looking for, what you need. Just wondering, just with the one-year data on the tape and the real-world experience now, was there any friction or just, I guess, patient hesitance or physician hesitance in terms of that real-world data now that it's in place? Could that just help the commercial outfit? I think the answer could be, I don't know if it's obvious, but a yes. I think the other angle is just with pump partners seeing that one-year data, giving them more confidence to move forward with the partnership. Two different channels, but same question. Yeah, I think, Josh, I'd say apprehension was there, and I think on our behalf as well. We saw it in the clinical trial, was it going to work like that in real life? When Fran presented that in Barcelona, it was one of the happiest days of my life because it wasn't just good data, it was great data. We're able to say that more confidently now in our conversations with our physicians. We never get pushed on the performance, but was it going to survive? Are we going to have to explant and put new ones in? We saw really good performance in the first year of the product. Yes, talking to the pump partners, this certainly helps that our product is working, and the data from the Sequel product, the twiist product, is helping, and the success we're having is helping my conversations, to say the least. All of it is on the upside. Thanks. I think also the data is coming at a time where there's been some reliability and accuracy issues within the field with some of the other CGM players and their technologies. Was hoping to just, I think we had a discussion yesterday, just wanted to build on it, just about quality assurance steps, what your competitor's quality assurance program is versus Senseonics. I think my new understanding is that I think every Eversense 365 device goes through some sort of testing before it's released, and that may be different and a higher level of quality assurance than some of the competitors. Thanks for taking the questions. Yeah, Josh. One of the big differences in our technology is that every sensor goes through the quality assurance. Instead of doing a batch processing at the end like every other manufacturer does, we have a sensor that gets calibrated. Each sensor has its unique calibration. It sends the data from manufacturing onto the cloud, and that's what we retrieve and take back. That's how we start. That leads to higher accuracy because now they are tailored to each sensor. It gives us much more control on the quality of it. It's never good when anybody goes through in the industry, when others go through those quality issues. It erodes the confidence of the patient and the provider, so that's not good for any of us. We do make sure that we try to stay clear of it. One of the very timely things. I called Mukul the other day. I said, "What happens if somebody steals some of our sensors in shipping?" It unfortunately happens. Well, the reality is, those sensors are turned off in the cloud. Even if you got access somehow to an expired or a stolen Eversense sensor, you're never going to be able to activate it because each individual sensor is controlled through linking to the cloud. Just a fundamentally different technology. Great. Thanks, guys. Good morning, Jon Block with Stifel. Maybe Dr. Ahn, to start with you, just at a high level, have you seen the awareness increase from your patient base around 365 as the company's leaned in a little bit from a DTC perspective? I'm just curious, for those that are not aware and you broach the subject, call it, can you maybe talk a little bit about what you're seeing in terms of success or the conversion rate over to 365? Yeah. I think one of the things that I've been excited by, as someone who wants more options for my patients, is just I'm a very online person for better and worse, and I think that just the public discourse that I see on different, whether it's Facebook, whether it's Reddit, whether it's Instagram and TikTok, I think there's, in the comments, if you look at pretty much any complaint thread of transcutaneous sensors. There'll always be people now popping up saying either, "I've tried Eversense," or, "I'm thinking about Eversense." On the twiist user groups, I think there's a lot of clamoring for Eversense. I think it's starting to get that kind of like, "Oh, what is that other sensor that we're hearing about that seems to have less issues?" I'm seeing that in my practice, too. Before, I'd kind of be like, "Hey, here's the Eversense." People are like, "Okay, okay, come on. Let's get to the real ones." Now it's kind of like, "Oh, okay. I can see why no pressure lows is a really good benefit." I think the public perception seems to be improving and the awareness is really going up, I think both as a combination of direct-to-consumer marketing and also some of the struggles that other sensors are going through. That was great. Maybe just a follow-up. I'm not going to ask on the pump integration side, the timing. Brian, don't worry, I won't go there. I'm just curious, for Gemini and twiist, when you guys next year release Gemini, what needs to be done from that integration standpoint, if anything? When we think about additional pump providers coming on board, as you guys talked about, you're closing in on Gemini, you seem to have a good line of sight per the trials. Should we be thinking an additional partnership is likely post-Gemini with other players rather than pre? Thank you. I think I got this one. For Gemini, nothing would change for integration with AID because we'll keep the same transmitter. It'll only transmit and talk to a pump when the Bluetooth is on on the transmitter. In the flash mode, you're not really transmitting to the pump. Nothing is changing with Gemini. With Freedom, the Bluetooth coming from the sensor will change. Now will be different Bluetooth protocol, trying to conserve all the power. Those will have to be updated. Thank you. Anthony from Mizuho. Thanks for the Analyst Day and all the updates. Maybe for Dr. Ahn, when you think about just an inflection point for 365 implantable sensor, we have Gemini and Freedom coming. How much of a big deal from just patients that you're hearing would be to get rid of the on-body sensor? Is that a key inflection point? Gemini itself obviously has better connectivity and communication directly with phones. How big of a leap step for users is connectivity with the phone and lack of an on-body transmitter in the next two years? I'll have a follow-up. Yeah, I think my area of interest is Type 1 diabetes. I think in the Type 1 diabetes population, removing the on-body system is massive. I think that cannot be understated. I think Freedom is really groundbreaking, and I think that will be really exciting when that happens. I've been thinking about it a lot over the past 24 hours. I think Gemini could potentially be very exciting for the Type 2 population. I think one of the things I'm noticing with these over-the-counter systems that I think people might have expected to maybe have more market share, is that I think people don't want things to be visible. You know what I mean? If you have Type 2 diabetes and you can just flash your CGM data, I think that could be a very appealing opportunity for people. I think in the Type 1 population, I think removing the transmitter all the time is huge. I think in the Type 2 population, that could make it a real big unlock. Yeah. Does that make sense? No, it does. Almost segregating. I guess the follow-up is for Rick. When we look ahead to our models in that 2027, 2028, even 2029 timeframe now, you have reorders in there. You're going to have three options available. How do you think about reorders once we get into that era? Thanks. Three options. I think we'll see which products are on market. I think the reimbursement is pretty consistent. I don't know if we'll be able to ask for premiums, so we'll certainly try, and then we'll use specific products probably for specific markets. When we get to Freedom, I think that can be a product for both Type 1 and Type 2. Can you hear me okay? Just a couple quick ones. One, I'd love your thoughts on ketones. Is it an opportunity? Is it a threat? Just general thoughts. Ketone sensing. Ketones, certainly something, Jason, that we're absolutely looking at. We've actually done some of the experimental investigation to do that. Right now, as many of you know, we do actually have a multi-channel analyte sensor. We've actually done the same thing for lactate. Ketones can be important. There's a lot of press on it right now in the Type 1 space. As another level of protection, I can see it having a role, especially in pediatrics. It doesn't really have the same benefit in the Type 2 space, and most of our patients are Type 2. At this point, we're going to watch and to really see how the market acceptance is up on it. For some of you may know, my background is actually out of Abbott. We produced a ketone strip there, we could never really get any uptake on it. I see the safety value of it. I understand the reason why Abbott and Dexcom may be competing against it with their similar products, but we'll add it into our chemistry if it really makes sense and the clinical acceptance is there. Thanks. One for Dr. Kaufman. Just on the data you presented, I think it was 5,000 patients, patient care user characteristics. It was like 25% Type 1, 50% some odd Type 2, and there was 18% not reported. I don't know if that was just a general sampling dynamic or the real question is, are you seeing use outside of people with diabetes? No, I think it's a reporting issue. We see the same when we ask them their gender, about a third don't report. The age, about 25% didn't report. I think there's a group of people who just don't want to give up their own statistics. Thank you. I'm going to take the opportunity to ask a question that I could ask David, since I noted your 350 sensor insertions, removals. Your perspective, people say, "Geez, we put this sensor in. Does it ever move? Does it ever migrate?" Where is this sensor on those 350 when you go to take it out? Great question. Yeah. It doesn't migrate. I get that question a lot. I know with Implanon and Nexplanon, there's stories of migration, but I've never seen the sensor migrate. It might tilt a little bit, but it's in essentially the same spot. I've never seen it migrate. Can you follow up on just the explant procedure and just how simple or hard it is? I was among one of the early adopters. There was a learning curve with the removals more so than the insertions. I have a clinician, a physician in my office, and he just started doing his first removals in the past three months, and I was not involved in his training at all. I was expecting kind of a call. I was expecting to give him a pep talk, but I didn't even realize he was doing removals until after he had done like five or six and I was like, "Oh, I didn't even know you started doing removals. How was it?" He was fine. I don't know if the training systems got better, or if he's just really talented, but I haven't seen it come up. [audio distortion] I think so. I'm happy to talk to people and kind of give them my tips, but they've been really good about gathering my feedback, so maybe they're incorporating what I would have told him to their trainings, and hopefully it's helped them out. Yeah, I was probably among the first people to get trained, that was back in 2018, literally. Yeah. Even with the Ozempic effect, we've certainly seen patients lose 50 lbs- 100 lbs while that year duration, and it's still in the same place. It may be a little saggier, but it's retrievable. Anthony again from Mizuho. Maybe looking at the capital raise and the efforts on DTC, just a recap on where the dollars are being placed regionally in the country, which new areas are you looking to open up now that you're capitalized? When you really make that push DTC into a local region, what is the sort of turnaround factor or return profile of that as to when you actually see traction from a new patient implant standpoint? Brian, do you want to talk about the audiences and targeting? Anthony, we really do geo-fence our spend. We started with 50 mi from an existing inserter, then we moved it to 75 mi, then some markets, we move it to 100 mi. Once you get past 100 mi, we know that someone probably isn't going to drive 150 mi or 200 mi to get a sensor implanted. If we start spending it in areas where we don't have inserters or we don't have reps to help the physician get onboarded, then we're just wasting our dollars. As we can expand our territories, as we can expand our Eon Care facility, as we can expand additional insertion capabilities, then we do our DTC advertising on top of that. Our agency has every zip code. It's a pretty cool program that is used for it. We do try in certain areas to expand it a little bit, and certainly in rural areas, that helps a little bit more. Once we see success in certain markets, we actually put more dollars in those markets. I was with our biggest account from San Antonio last night, and they wanted to see the data as to what they're benefiting from. I can literally take it down to an account level. I can see every channel that we use. I can see every ad that we use. We can move them into different modalities, and we truly change things quite often. As soon as they start to get hot, we pour more on that particular ad, that ambassador, that eight-second clip. It's pretty high tech these days. Meta went down here about two weeks ago for about 36 hours, you would have thought our company was ending because we had 50 people sitting inside with not a whole lot coming in, right? That's how detailed that all gets. Our workable lead percentage is up because we can, to some extent, target those that are on insulin, those that are at the Medicare. Some of our ads are Medicare-focused, for instance, and it drives a higher percentage in on a very profitable segment for us. I could go on for hours, and John Bradford's here. You want to stop by and get versed on what DTC looks like from an expert, come talk to my head of marketing. It's truly amazing. From an economic perspective, we spent about $13 million in the back half of last year. We learned a lot from that, and we're taking the same amount and spreading it over the entire year and seeing improvements in the cost per workable lead, cost per opportunity. As leads come in, we categorize them as low, medium, and high. The medium leads convert twice as good as a low and the high-quality leads convert twice as good as a medium. We're making the investments and the efficiency with the agency on getting more of those medium and high-quality leads. As Brian said, we're looking at where the appropriate regions are to turn up the DTC spend or add more to it. I'd just say lastly, our inside team is doing a great job. I've had almost no turnover in there. Ed Monas came from Medtronic with tremendous experience, worked for Jeff for several years. Snagged a few folks from Tandem over and stuff, and that team is really rocking right now. If that team isn't working, then you can do all the DTC in the world, and if it comes in and we don't handle it, then it's just a frustration to the patient. We meter it by what we can do internally right now, and as we get to the second half of the year, we'll add a few more in there because we're going to dial it up a little bit. It is a finely oiled machine finally, and I'm really happy with what we're seeing. Maybe just for the physicians, when you think of an implantable one-year sensor, certainly makes sense that there's a gating factor. Obviously, the implant and explant, understand that. But where do you think a well-oiled implantable CGM can be as a percent of your patients, five years from now? Can an implantable option be 10% of the market, you think? Is that reasonable? Yeah. Yes, I do. I'm not good at doing these numbers things. I'm just a clinician, but 10% to me sounds low. For a Freedom system, that's what people want. That's what people have been dreaming about. You want nothing visible. You want it to be all implant. You don't want the disease to be visible. That's literally half of what we do in helping people with Type 1 diabetes. I think you see the same thing in Type 2 as well. Yeah, in my opinion, 10% seems low, but I'm just a clinician. When I show the data that we skew to an older population, it's because the device really is geared toward that. You get to the Medicare age range with maybe some dexterity issues or visual issues or cognitive issues. Having an implant one time a year makes a lot more sense than having to repeatedly change the sensor yourself or wait till your daughter comes to change your sensor. The characteristics that we have, that on-body vibratory alert, which enables them if they're having hearing or visual deficit. There's a lot of characteristics for the older population where I think the transcutaneous sensors just don't address their needs as well. All right. Thank you, everybody, for joining us today. Enjoy the good.